STOCK TITAN

Dexcom (DXCM) director shifts 10,148 shares from direct ownership to revocable trust

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Dexcom Inc. director Richard Alexander Collins reported internal share transfers involving 10,148 shares of common stock. On 2026-05-08, 5,074 shares moved from his direct ownership to the Richard A. Collins Revocable Trust, with both legs reported as bona fide gifts. After these entries, he holds 40,162 Dexcom shares indirectly through the trust and no shares directly.

Positive

  • None.

Negative

  • None.

Insights

Form 4 shows routine internal transfers, not market buying or selling.

Director Richard Alexander Collins reported two G-code (bona fide gift) transactions totaling 10,148 shares of Dexcom Inc. common stock. Footnotes explain these reflect a transfer from direct ownership into the Richard A. Collins Revocable Trust tied to vesting of restricted stock units.

Economically, this is a reclassification of how the shares are held, not an open-market trade. Following the transactions, Collins holds 40,162 shares indirectly via the trust and zero directly. With no shares bought or sold in the market, the filing is informational and does not, by itself, signal a change in his outlook on Dexcom.

Insider Collins Richard Alexander
Role null
Type Security Shares Price Value
Gift Common Stock 5,074 $0.00 --
Gift Common Stock 5,074 $0.00 --
Holdings After Transaction: Common Stock — 0 shares (Direct, null); Common Stock — 40,162 shares (Indirect, by Trust)
Footnotes (1)
  1. Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust upon vesting of previously awarded restricted stock units. Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.
Shares transferred per leg 5,074 shares Each G-code transaction on May 8, 2026
Aggregate shares in G-code entries 10,148 shares Total across two bona fide gift entries
Indirect holdings after transfer 40,162 shares Held by Richard A. Collins Revocable Trust after transactions
Direct holdings after transfer 0 shares Directly owned by Collins after May 8, 2026 transactions
Transaction date May 8, 2026 Date of reported G-code transactions
bona fide gift financial
"The transaction code description for each entry is “Bona fide gift”."
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
restricted stock units financial
"Shares were transferred upon vesting of previously awarded restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
revocable trust financial
"Shares are held by the Richard A. Collins Revocable Trust."
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
indirect ownership financial
"Indirect ownership is reported as by Trust with 40,162 shares following the transaction."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collins Richard Alexander

(Last)(First)(Middle)
6340 SEQUENCE DRIVE

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026G5,074(1)D$00D
Common Stock05/08/2026G5,074(1)A$040,162Iby Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust upon vesting of previously awarded restricted stock units.
2. Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.
Remarks:
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Richard Alexander Collins05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dexcom (DXCM) director Richard Collins report?

Director Richard Alexander Collins reported two Form 4 transactions coded as bona fide gifts involving 10,148 Dexcom common shares. Footnotes clarify these reflect an internal transfer of 5,074 shares from direct ownership into his revocable trust following vesting of restricted stock units.

Did Dexcom (DXCM) director Richard Collins sell any shares in this Form 4?

No, the Form 4 does not show any open-market sales. The transactions are reported as bona fide gifts, reflecting an internal transfer of 5,074 shares from direct ownership to a revocable trust, rather than a sale for cash consideration in the market.

How many Dexcom (DXCM) shares does Richard Collins hold after the reported transactions?

After the reported transactions, Richard Alexander Collins directly holds zero Dexcom shares. He indirectly holds 40,162 common shares through the Richard A. Collins Revocable Trust, where he serves as a trustee, according to the footnote describing the trust’s ownership structure.

What is the significance of the G transaction code in the Dexcom (DXCM) Form 4?

The G transaction code on the Form 4 indicates a bona fide gift. In this case, it is used for a transfer of Dexcom common shares associated with restricted stock unit vesting and movement from direct ownership into a revocable trust, not for an open-market sale or purchase.

How many Dexcom (DXCM) shares were transferred by Richard Collins on May 8, 2026?

On May 8, 2026, Form 4 data show 5,074 Dexcom common shares moved from Richard Collins’s direct ownership to his revocable trust, with 10,148 shares reflected across two related G-code entries. The footnotes explain these entries as a transfer tied to vested restricted stock units.

Does the Dexcom (DXCM) Form 4 indicate remaining derivative positions for Richard Collins?

No remaining derivative positions are shown in the provided data. The derivative summary is empty, and the footnotes instead focus on the transfer of vested restricted stock unit shares into the revocable trust, clarifying the nature of Collins’s current equity holdings in Dexcom.